Physician profile
Sidharth Chandra
NPI 1295140143
$6,646.26
in general payments reported to CMS, 2019-2025
24 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $158 · 2021: $529 · 2022: $811 · 2023: $1,139 · 2024: $1,076 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,988 · Education: $7.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,987.82 |
| Education | $7.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,034.17 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $872.79 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $611.41 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $578.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $391.91 | 2020-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $360.99 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $322.26 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.82 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $236.14 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $154.46 | 2019-2022 | |
| Braeburn INC. | $145.33 | 2024-2025 | Brixadi |
| Indivior INC. | $119.65 | 2020-2024 | Perseris |
| Lundbeck LLC | $114.59 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $97.43 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $60.18 | 2022-2023 | Belsomra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.97 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.80 | 2019 | |
| Insulet Corporation | $39.69 | 2024 | Omnipod |
| Idorsia Pharmaceuticals US INC | $28.77 | 2022 | |
| Eisai INC. | $20.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.78 | 2023 | Qelbree |
| Pfizer INC. | $18.39 | 2023 | |
| Sanofi Pasteur INC. | $17.46 | 2023 | |
| Avanir Pharmaceuticals, INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidharth Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.